L-759,656

L-759,656
(IUPAC) ime
	(6aR,10aR)-1-metoksi-6,6-dimetil-9-metiliden-3-(2-metiloktan-2-il)-7,8,10,10a-tetrahidro-6aH-benzo[c]hromen
Klinički podaci
Identifikatori
CAS broj	.
ATC kod	nije dodeljen
PubChem	5311216
Hemijski podaci
Formula	C26H40O2
Mol. masa	384,593 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C26H40O2/c1-8-9-10-11-14-25(3,4)19-16-22(27-7)24-20-15-18(2)12-13-21(20)26(5,6)28-23(24)17-19/h16-17,20-21H,2,8-15H2,1,3-7H3 ; Key: BJIIKHXAZBTGLF-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

L-759,656 je analgetski leki koji je kanabinoidni agonist. On je visoko selektivan agonist za CB₂ receptor, sa selektivnošću od 414x za CB₂ u odnosu na CB₁,^[3] mada još uvek nije selektivan u istoj meri kao noviji agonisti poput HU-308.

On proizvodi slične efekte sa drugim kanabinoidnim agonistima poput analgezije, ali sa malo ili bez sedativnih ili psihoaktivnih efekata usled slabe CB₁ aktivnosti. On ima relativno jako antiinflamatorno dejstvo usled jake aktivnosti na CB₂.^[4]^[5]

Reference uredi

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Ross, R.; Brockie, H.; Stevenson, L.; Murphy, V.; Templeton, F.; Makriyannis, A.; Pertwee, R. (1999). „Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630”. British Journal of Pharmacology 126 (3): 665–672. DOI:10.1038/sj.bjp.0702351. PMC 1565857. PMID 10188977.
↑ Huffman, J. W. (2000). „The search for selective ligands for the CB2 receptor”. Current pharmaceutical design 6 (13): 1323–1337. DOI:10.2174/1381612003399347. PMID 10903395.
↑ Huffman, J. W. (2005). „CB2 receptor ligands”. Mini reviews in medicinal chemistry 5 (7): 641–649. DOI:10.2174/1389557054368844. PMID 16026310.

Vidi još uredi

Spoljašnje veze uredi

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Ross, R.; Brockie, H.; Stevenson, L.; Murphy, V.; Templeton, F.; Makriyannis, A.; Pertwee, R. (1999). „Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630”. British Journal of Pharmacology 126 (3): 665–672. DOI:10.1038/sj.bjp.0702351. PMC 1565857. PMID 10188977.

[4] Huffman, J. W. (2000). „The search for selective ligands for the CB2 receptor”. Current pharmaceutical design 6 (13): 1323–1337. DOI:10.2174/1381612003399347. PMID 10903395.

[5] Huffman, J. W. (2005). „CB2 receptor ligands”. Mini reviews in medicinal chemistry 5 (7): 641–649. DOI:10.2174/1389557054368844. PMID 16026310.

[3]

[1]

[2]

[4]

[5]